Otsuka Begins Paediatric MDR-TB Trials

Enrollment has begun for a ground-breaking clinical program exploring the use of delamanid in paediatric multidrug-resistant tuberculosis (MDR-TB). Otsuka is the first company to perform a trial among this population for regulatory approval. The programme will also evaluate the bioequivalence of a dispersible formulation for use with younger children and infants.

Childhood TB is a neglected segment of an already neglected disease. The WHO estimates that there are a half-million cases of childhood TB resulting in 64,000 deaths worldwide. In a recent report, the European Medicines Agency highlighted the success of paediatric regulation in spurring high-quality research, better information on the use of medicine in children and more age-appropriate formulations (

A recommendation on the use of delamanid in adult MDR-TB patients is expected later this month from the European Committee for Medicinal Products for Human Use. The compound is also under regulatory review in Japan and a Phase 3 trial in adult MDR-TB patients is already underway, including those with co-existing HIV infection.

For more information, contact

For more information on delamanid go to

More News
5 Jun 2019
**Update: The US FDA Antimicrobial Drug Advisory Committee voted in favor of the NDA 14 to 4 on June 6th, 2019** The United States Food & Drug Administration (FDA) will host the Antimicrobial Drug Advisory Committee on Thursday, June 6th to discuss the new drug application (NDA) involving new...
21 Mar 2019
On December 6, 2018, at 7AM EST, TREAT TB will host a capacity building webinar on community engagement in MDR-TB clinical trials. It will feature a presentation from Ezio Tavora dos Santos Filho, STREAM Community Engagement Coordinator from REDE-TB , followed by a question and answer session. The...
12 Mar 2019
On March 8th, TB Alliance announced its novel compound, Pretomanid, is currently being reviewed by the FDA for use against Tuberculosis. TB Alliance's press release can be found below: NEW YORK, NY (March 8, 2019)—TB Alliance’s new drug application (NDA) for the novel tuberculosis (TB) drug...